ArticleCancers2010
YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Trial
- Gene and Protein Profiles of CHI3L1 and CHI3L2 in Patients with Rheumatoid Arthritis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Targeting of YKL-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding.Current gene therapy · 2026Review
- YKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation.International journal of molecular sciences · 2025Review
- YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model.Scientific reports · 2025Article
- Heparin-binding of the human chitinase-like protein YKL-40 is allosterically modified by chitin oligosaccharides.Biochemistry and biophysics reports · 2025Article
- Review
- Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.Heliyon · 2024Article
- The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis - A Single Centre's Experience.CNS & neurological disorders drug targets · 2024Observational
- Prognostic and predictive role of YKL-40 in anal squamous cell carcinoma: a serological and tissue-based analysis in a multicentric cohort.Frontiers in medicine · 2024Article
- YKL-40 serum levels are predicted by inflammatory state, age and diagnosis of idiopathic inflammatory myopathies.Scientific reports · 2023Article
- Recent advances in label-free optical, electrochemical, and electronic biosensors for glioma biomarkers.Biomicrofluidics · 2023Review
- Conserved YKL-40 changes in mice and humans after postoperative delirium.Brain, behavior, & immunity - health · 2022Article
- Article
- Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma.Frontiers in oncology · 2022Article
- The Perspectives of Biomarkers in Predicting the Survival of the Renal Graft.Frontiers in pediatrics · 2022Review
- YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia.Molecular and clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
YKL-40 is a 40 kDa glycoprotein produced by cancer cells, inflammatory cells and stem cells. It probably has a role in cell proliferation and differentiation, inflammation, protection against apoptosis, stimulation of angiogenesis, and regulation of extracellular tissue remodelling. Plasma levels of YKL-40 are often elevated in patients with localized or advanced cancer compared to age-matched healthy subjects. Several studies have demonstrated that high plasma YKL-40 is an independent prognostic biomarker of short survival in patients with different types of cancer. However, there is not yet sufficient data to support determination of plasma YKL-40 outside research projects as a biomarker for screening of gastrointestinal cancer and determination of treatment response and poor prognosis before or during treatment and follow-up. Plasma YKL-40 is also elevated in patients with other diseases than cancer, e.g., severe infections, cardiovascular disease, diabetes, chronic obstructive lung disease, asthma, liver fibrosis and rheumatoid arthritis. Co-morbidity should therefore always be considered in patients with cancer, since other sources than cancer cells can increase plasma YKL-40 levels. Future focused translational research projects combining basic and clinical research are needed in a joint effort to answer questions of the complex function and regulation of YKL-40 and the question if plasma YKL-40 is a clinical useful biomarker in patients with cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.